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A tissue plasminogen activator was extracted from 
skin lesions with allergic vasculitis and purified by suc-
cessive column chromatography on Sephadex G-200, 
DEAE-cellulose, Hydroxyaptite-cellulose and polyacryl-
amide gel electrophoresis. By these procedures, 160 p.g 
of enzyme with a specific activity of 843.8 international 
units/mg protein was obtained from 5 g of original skin. 
The purified material was homogeneous as ascertained 
by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and had an apparent molecular weight of 
110,000 as measured by gel filtration on Sephadex G-200. 
Its identity with human urokinase was investigated and 
was found to possess the same plasminogen activator 
activity as that of urokinase. It had high amidolytic 
activity, but only slight N-a-acetyl-glycyl-L-lysine 
methyl est~r esterolytic activity. This tissue plasmino-
gen activator was confirmed to be immunologically iden-
tical to human urokinase. 
Lever [1] described allergic vasculitis as a skin disorder in 
which purpilric lesions are usually present. It is characterized 
histologically by damage to the small cutaneous vessels and a 
neutrophilic inflltrate showing karyorrhexis. However, the con-
ception of allergic vasculitis has still not been established be-
yond the definition of Ruiter and Brandsma [2]. Although 
Cochrane [3] and Katz, Unanue and Dixson [4] reported that 
antigen-antibody complexes deposit in small blood vessels and 
induce excessive deposition of fibrin which rnight_initiate al-
lergic vasculitis, its pathogenesis also has not been clarified. 
Since Cunliffe [5] reported decreased blood fibrinolytic activity 
in patients with cutaneous vasculitis, many r eports have been 
accumulated on the role of the fibrinolytic enzyme system in 
cutaneous vasculitis . Cunliffe and Menon [6] r eported de-
creased blood fibrinolytic activity in six of nine patients with 
eryth ema nodosum, and Chaek, Arnowski, and Izak [7] in 6 of 
9 patients with Behc;et's disease. Sun et al [8] also reported that 
ilirninished tissue lytic activity was recognized in the patient's 
skin when measured by Todd's method [9]. Contrarily, it has 
also been reported that the bloqd fibrinolytic activity of patients 
with allergic vasculitis was increased. Robby et al [10] and Gola 
[11] reported some cases of allergic vasculitis which was fol-
lowed by disseminated intravascular coagulation (DIC). The 
authors [12] also reported 2 cases of allergic vasc•1litis who 
showed a significant shortening of euglobulin lysis time (ELT) , 
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but the cause for this is not clear. In the present study, the 
authors succeeded in extracting a tissue plasminogen activator \ 
from skin lesions with allergic vasculitis which is thought to be 
a responsible factor for the significant shortening of ELT. Some 
of its biochemical and immunological characteristics are also 
presented. 
MATERIALS AND METHODS 
Commercial Preparations 
The following commercial preparations were used: Bovine fibrinogen 
(type-!, Wako Pure Chern. Co., Ltd.), Bovine plasminogen free fibrin-
ogen (type-Il, Daiichi Pure Chern. Co., Ltd.), Bovine thrombin (Mach-
ida Pharm. Co., Ltd.), a-N-p-Tosyl-L-arginine methyl ester (TAMe) 
(Sigma), Casein nach Hammarsten (Merck), N-a-acetyl-glycyl-L-Iysine \ 
methyl ester (AGLMe) (The Foundation for Promotion of Protein 
Research, Osaka), Chromogenic substrate S-2444 (pyro-Giu-Gly-Al·g-
pNA) (Kabi Diagnostica, Sweden), Sephadex G-200 (Pharmacia), 
DEAE-cellulose (Brown, 0.85 mEq/g, Lot No. 2256), Hyru·oxyapatite 
(Seikagaku Kogyo Co., Ltd.), Cellulose Mikrokristallin (Merck). 
Assay of Blood Fibrinolytic Enzyme System 
Measurement of EL T , fibrinogen and plasminogen contents was 
performed by the method described in a previous report [12]. The titre 
of serum fibrin(ogen) degradation products (FDP) was measured using 
FDP-latex agglutination test ki ts (Teikoku Zoki Pharm Co., Ltd.). 
Patient 
A 65-yr-old man was admitted because of purpura, painful and 
pruritic nodules, vesicles, ulcerations, arthralgia and a 39°C fever. The 
eruptions had persisted for 2 yr. The patient was diagnosed as a chJ·onic 
Gougerot-Ruiter type of allergic vasculitis based on clinical symptoms 
and histological features. Despite therapy with corticosteroids, anti-\ 
fibrinolytic agent (tranexamic acid) and diaminodiphenylsulfone (Dap· 
sone), the eruption failed to clear up completely. Two months after 
admission, purpura became severe and the painful nodu les on both 
extensor surfaces of the elbow joint became enlarged, tender, and 
gangrenous. Compared with the initial coagulationfibrinolysis test re-
sults, the EL T shortened from 380 to 240 min, fibr inogen ru·opped fTODl 
350 to 150 mg/ dl, plasminogen decreased from 5.5 to 2.7 casein units/ 
ml and the titre of FDP became elevated from 10 to 180 llg/dl. On the\ 
basis of these results, the authors considered that the severity of the 
skin lesions, might be due to increased blood fibrinolytic activity. 
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Extraction of Tissue Plasminogen Activator from Shin Lesions 
In the present study, the authors assumed that the increased blood 
fibrinolytic activity might be due to the liberation of fibrinolytic en· 
zymes such as plasmin or tissue plasminogen activator into blood from\ 
the skin lesion, and tried to extract such enzymes from the lesion. A 
skin sample was removed and thoroughly cleaned free of subcutaneous 
fat, washed in cold deionized water and frozen at -20°C for 24 hr. The 
frozen skin (5 g) was minced with scissors and homogenized with Virtis· 
Homogenizer (Virtis Co., Ltd.) in 10 volumes (w/ v) of 2 M KSCN 
solution according to the method of Astrup [13] without the acidifica· 
tion step. The homogenate was maintained at 4°C overnight and then 
centrifuged at 4 °C for 30 min at 15,000 xg. The supernatant was filtered 
through glass fiber and dialyzed for 12 hr at 4°C with 0.1 M phosphate 
buffer at pH 7.4. The dialyzed ftltrate was concentrated to one-tenth of 
its original volume by ultrafiltration. 
Prepctration of Standard Human Plasminogen and Plasmin 
Standard plasminogen and plasmin were prepared accordi.ng to the 
method described in previous reports [14,15]. 
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Estimation of the Fibrinolytic Activity and Protein Concentration of 
Sample 
The plasmin activity of the sample was estimated by the plasminogen 
free fibrin plate method of Astrup and Mullertz [16] and the estero lytic 
and caseinolytic assay methods as described in previous reports [17, 
18]. Estimation of the plasminogen activator activity of the sample was 
performed directly by standard fibrin plate method of Astt·up and 
Mullertz (16] and indirectly by esterolytic and caseinolytic assay meth-
ods using standard human plasminogen. AGLMe esterolytic activity of 
t he sample was measured by Hestrin's method [19] as modified by 
Roberts [20]. Amidolytic activity of the sample was also measured 
using S-2444 by the method as described in a previous report [21]. In 
' the present study, plasminogen activator ac tivity was calculated from 
each standard cUl've of urokinase (UK) which had been prepared in 
advance and expressed in international units (IU) of UK. One IU of 
UK produced 300 mm2 of lysis area on a standard fibrin plate and 
showed 0.0025 of absorbance change at 405 nm per min when its 
amidolytic activity was measured using S-2444 under standard condi-
t ions. Protein concentration was estimated according to the method of 
Lowry et al [22] using bovine serum albumin (Merck) as reference 
protein. 
Electrophoretic Technique 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was carried out by the method of Weber and Osborn [23] using 
7.5% gel with 1% SDS and 8 M urea. Electrophoresis was performed at 
8 rnA/gel for 3 h1·. Gels were stained for 2 hr with 2% Coomassie 
brilliant blue and destained electrophoretically. 
Estimation of Molecular Weight. 
The molecular weight of the purified tissue plasminogen activator 
was estimated by the method of Andrews [24). Sephadex G-200 (2.5 x 
50 em) was equilibrated with 0.05 M Tris-HCl buffer, pH 7.5 containing 
0.2 M KCl and elution was performed at 4 °C at a flow rate of about 15 
ml/hr. 
Preparation of the Immunoglobulin G (lgG) Fraction. of Anti- UK 
Rabbit Serum 
UK preparation (Mol wt, 53,000) was purified from a commercial 
preparation (The Green Cross Co., Ltd.) by affinity chromatography 
on [N"·(E-aminocaproyl)-DL-homoarginine hexylester]-Sepharose col-
umn followed by Sephadex G-100 gel filtt·ation, as described by Sumi, 
Sasaki, and MUl'amatu [25]. Its specific activity was 87,000 IU/ mg 
protein, and its homogeneity was confirmed by SDS-PAGE. A rabbi t 
was immunized by foot pad injections with 0.5 mg (43,500 IU) of highly 
pUl'ified UK in Freund 's adjuvant and given a single booster injection 
of the same amount 4 weeks later. After 4 weeks, a blood sample was 
drawn from the rabbit and incubated at 37°C for 3 hr and at 4 °C for 18 
hr before sepru·ating the serum by centrifugation at 2,500 .xg. The IgG 
fraction was separated from serum by the following methods of am-
monium sulfate fractionation (35% saturation) and DEAE-cellulose 
column chromatography (10-fold concentrations against the original 
antiserum). Specificity of the anti-UK rabbit IgG was examined ear lier 
by double immunodiffusion, immunoelectrophoresis, and its neutrali-
zation for pUl'ified UK. The anti-UK rabbit IgG gave only a single 
immunoprecipitin line on double immunodiffusion against purified UK, 
while on immunoelectrophoresis against the anti- UK rabbit IgG, puri-
fied UK (870 IU) gave a single precipitin arc wilh mobility between tr2 
and f31 globu lin. Also, l mg of IgG could neutra lize a lmost completely 
80 IU of purified UK when fibrinolytic activity of IgG-UK mixture was 
measured by the standru·d fibrin plate method . 
Immunologic Experiments 
Double-diffusion analysis (Ouchterlony method) [26] was performed 
at room temperature for 24 hr in 1% agru·ose (Behringwerke) in verona! 
buffer (!1- = 0.05, pH 8.6) containing 0.05% NaNa. Immunoelectropho-
resis was run in 1% agarose in the srune buffer at pH 8.6. 
RESULTS 
Measurement of Plasminogen Activator Activity in Shin 
Extract 
The fibrinolytic activity of the skin extract was measured 
fn·st by the plasminogen free fibrin p late method, but no activity 
could be detected. Next, the plasminogen activator activity in 
the skin extract was examined by plotting 0.02 ml of the skin 
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extract on a standard fibrin plate. As shown in Fig l, the skin 
extract produced lysis areas on the plate as did the control of 
UK, and the diameter of the lysis area produced by 0.02 m1 of 
the sample corresponded to that by 2 IU of UK. 
The plasminogen activator activity in the skin extract was 
further measured by the esterolytic and caseinolytic assay 
methods using standard plasminogen. As shown in Table I the 
skin extract converted the standru·d plasminogen into a~tive 
plasmin which possesses TAMe esterolytic and caseinolytic 
activities. It was also confirmed that the results of activity 
determined by the standard fibrin plate method correlated well 
with those determined by the esterolytic and caseinolytic assay 
methods. 
Measurement of AGLMe Esterolytic and the Amidolytic 
Activities of'the Shin E xtract 
As it was confirmed that the skin extract possessed the same 
plasminogen activator activity as UK, the AGLMe esterolytic 
and amidolytic activities of the extract were compared with 
those of UK. Table I shows that the extract possesses a high 
amidolytic activity for S-2444, which is a specific chromogenic 
substrate for UK, but only slight esterolytic activity for 
AGLMe. 
Purification of the Plasminogen Activator in Shin Extract 
(PAS) 
PAS was purified by successive column chromatography on 
Sephadex G-200, DEAE-cellulose, Hydroxyapatite-cellulose 
and polyacrylamide gel electrophoresis (PAGE). Confirmation 
FIG 1. Plasminogen activator activity in skin extract (standru·d fibrin 
plate method). Commercial urokinase (UK) was dissolved in 0.1 M 
phosphate buffer (Na2-K, pH 7.2) before use and used as the standru·d. 
1; 0.1 M phosphate buffer (Na2-Na, pH 7.4). 2,3,4,5; 0.25, 0.5, 1.0, 2.0 IU 
of UK/ 0.02 mi. 6, 7; 0.01, 0.02 ml of test sample. 
TABLE I. Plasminogen a.ctiva.t01; AGLMe esterolytic and a.midolytic 
activities of shin. extract" 
Ass11y method Substrate IU.O.J 
Fibrin plate Standru·d plate 10.0 
Plasminogen method Activation method TAMe 11.0 
activator activity 
of standru·d Casein 10.5 
plasminogen 
AGLMe esterolytic Hestrin's method AGLMe 1.5 
activity 
Amidolytic activity Chromogenic S-2444 11.0 
substrate 
method 
" To determine the plasminogen activator activity using standru·d 
plasminogen, 0.1 ml of skin extract was added to test tubes containing 
0.1 ml of standru·d plasminogen, 0.5 ml of 20 mM TAMe (0.25 ml of 8% 
casein) and 0.3 ml (0.55 ml) of 0.1 M phosphate buffer at pH 7.4, after 
which each reaction tube was incubated for I hr at 37°C. To determine 
the AGLMe estero lytic activity, 0.1 ml of skin extract was added to test 
tubes containing 0.5 ml of30 mM AGLMe and 0.4 ml ofO.l M phosphate 
buffer at pH 7.4, after which each reaction tube was incubated for 1 hr 
at 37°C. To determine the amidolytic activity, 0.1 ml of skin extract 
was added to test tubes conta ining 0.1 ml of 3 mM S-2444 and 0.8 ml of 
Tris-HCI buffer at pH 8.8, after which each test tube was incubated for 
20 min at 37°C. 
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of PAS was achieved by its amidolytic and plasminogen acti-
vator activities in each fraction in the process of purification 
procedures. 
Step 1. Sephadex G-200 Column Chromatography 
A 3.3 x 42 em column of Sephadex G-200 was equilibrated 
with 0.1 M phosphate buffer at pH 7.4. Five ml of the skin 
extract (containing 680 IU) was applied to the column which 
was run at a flow rate of 18 ml/hr, and 5 ml fractions were 
collected. The distribution of proteins, amidolytic and plasmin-
ogen activator activities in each fraction are shown in Fig 2. 
Proteins were eluted as 4 main peaks and both amidolytic and 
plasminogen activator activities were eluted in the second pro-
tein peak. It was also confirmed that the amidolytic activity in 
each fraction correlated well with the plasminogen activator 
activity in each fraction. 
Step. 2. DEAE-cellulose Column Chromatography 
PAS fractions obtained from Sephadex G-200 column were 
collected and dialyzed overnight against 0.01 M phosphate 
buffer at pH 7.4 containing 0.05 M NaCl at 4°C. The dialyzed 
solution was chromatographed on a DEAE-cellulose column 
(2.0 x 8 em) which had been equilibrated with 0.01 M phosphate 
buffer at pH 7.4 containing 0.05 M NaCl. After washing with 
100 ml of the same buffer, the column was eluted with a linear 
gradient formed from 100 ml of equilibration buffer and 100 ml 
of 0.01 M phosphate buffer at pH 7.4 containing 0.3 M NaCl, at 
a flow rate of 20 ml per hr (5 ml per tube). As shown in Fig 3, 
PAS which possesses amidolytic and plasminogen activator 
activities was eluted in nonadsorbed fraction No. 4-8. These 
PAS fractions were collected and stored at 0°C until use. 
Step 3. Hydroxyapatite-cellulose Column Chromatography 
Hydtoxyapatite-cellulose was prepared by mixing HydToxy-
apatite and Cellulose Mikrokristallin in equal weight volumes 
in 0.01 M phosphate buffer at pH 7 .4. PAS fractions obtained 
from DEAE-cellulose column were dialyzed overnight against 
0.01 M phosphate buffer at pH 7.4 at 4 °C. The dialyzed solution 
was chromatographed on a Hydroxyapatite-cellulose column 
(2.0 x 8.0 em) which had been equilibrated with 0.01 M phos-
phate buffer at pH 7 .4. PAS was eluted with a linear gradient 
formed from 100 ml of equilibration buffer and 100 ml of 0.2 M 
phosphate buffer at pH 7.4, at a flow rate of 30 ml per hr (5 ml 
per tube). As shown in Fig 4, one main peak with amidolytic 
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FIG 2. Chromatography of plasminogen activator in skin extract (PAS) on Sephadex G-200 column. See text for details of column 
chromatography. To measure the amidolytic activity in each fraction, 
0.5 ml of each fraction was added to test tubes contain ing 0.1 mJ of 3 
mM S-2444 and 0.4 ml of Tris-HCl buffer, pH 8.8. After incubation for 
10 min at 37°C, the reaction was stopped with 0.1 ml of 50% acetic acid. 
The absorbance at 405 nm was measured against a substrate control. 
To measure the plasminogen activator activity in each fraction, 0.02 ml 
of each fraction was plotted on a standard fibrin plate. After incubation 
for 18 hr at 37°C, lysis area (mm2 ) was measured. (--) protein 
(0--0) arnidolytic activity (____.) plasminogen activator activity. 
Vol. 78, No.1 . 
and plasminogen activator activities was eluted in fraction No. 
31-37 which were then combined and lyophilized. 
Step 4. PAGE of PAS 
Partially purified PAS obtained from Step 3 was further ' 
characterized by PAGE (7%) according to Davis's method , 
[27]. Duplicate gels were run, one gel (Ca. 100 !J.g protein) was 
stained and the other was sliced in 2 111m segments and eluted 
overnight at 4°C with 0.9 ml of Tris-HCl buffer at pH 8.8. As 
shown in Fig 5, a major protein band segment, 11-13, and minor 
band segments, 5-6, 17-18, were found . The other gel, when 
sliced and eluted was tested for amidolytic and plasminogen 
activator activities of PAS. These activities were demonstrated 
in segment 11-13. The 3 sliced gel bands of PAS were collected 
and eluted, and purified PAS solution was lyophilized again to 
examine the immunological characteristics. The results of over-
all purification and yield of PAS are summarized in Table II. A 
final yield of 160 !J.g of PAS was obtained from 5 g of original 
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FIG 3. Chromatography of PAS on DEAE-cellulose column. See 
text for details of column chromatography. The amidolytic and plas· 
minogen activator activities in each fraction were determined as de· 1 
scribed in Fig 1. (--) protein (0--0) amidolytic activity (....__..) 
plasminogen activator activity. 
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FIG 4. Chromatography of PAS on Hydroxyapatite-cellulose col· 
umn. See text for details of column chJ"Omatography. The amidolytic 
and plasminogen activator activities in each fraction were determined 
as described in Fig 1. (--) protein (0--0) amidolytic activity (.__.) plasminogen activator activity. 
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FIG 5. Polyacrylamide gel electrophoresis of the Hydroxyapatite-
cellulose fraction of plasminogen activator in skin extract (PAS). Pu-
rified PAS (Ca. 100 p.g protein) was subjected to electrophoresis in a 0.7 
x 7 em polyacrylamide gel column. To determine the amidolytic activity 
in each gel, 0.9 ml of eluate was incubated with 0.1 ml of 3 mM S-2444 
for 10 min at 37°C. To determine the plasminogen activator activity, 
0.03 ml of eluate was plotted on a standard fibrin plate. (o--D) 
amidolytic activity (........_.) plasminogen activator activity. 
TABLE II. Summary of the purification of PAS 
HSE" 
Sephadex G-200 
DEAE-cellulose 
Hydroxyapatite 
PAGE 
" Human skin extract. 
Total 
activity 
(IU) 
680 
560 
410 
280 
135 
Total 
protein 
(m g) 
40 
11.6 
2.2 
0.73 
0.16 
Specifi c 
activity 
(IU / mg) 
17.0 
48.3 
186.4 
383.6 
843.8 
Recovery in 
tota l act 
(%) 
100 
82.4 
60.3 
41.2 
19.9 
skin . Its specific activity, 843.8 IU/ mg protein, when calculated 
from amidolytic activity well coincided with that from plasmin-
ogen activator activity by the standard plate method. 
Homogeneity 
The final preparation of PAS gave a single band m SDS-
PAGE (Fig 6). 
Estimation of Molecular Weight 
The approximate molecular weight of PAS was estimated by 
gel filtration on Sephadex G-200 column using the method of 
Andrews [24]. The molecular weight of PAS was found to be 
110,000 daltons, on the basis of the linear relationship between 
the elution volumes of marker proteins and the logarithms of 
their molecular weights. Bovine gamma globulin (160,000) , bo-
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FIG 6. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) of purified plasminogen activator in skin extract (PAS). 
Purified PAS (Ca. 50 p.g protein) was subjected to electrophoresis in 0.7 
x 8 em polyacrylamide gel column. Diluted sample consisted of 8 M 
urea, 1% SDS and 0.01 M phosphate buffer at pH 7.2. 
vine serum albumin (67,000), and ovalbumin (45,000) were used 
as marker proteins. 
Identity of PAS and UK 
From the substrate specific studies and biochemical proper-
t ies which were identified by pmification procedures, PAS was 
thought to be a UK-like enzyme. Therefore, to elucidate the 
identity of PAS with UK, the immunologic chamcterization of 
PAS was investigated. As shown in Fig 7, PAS formed a single 
immunoprecipitin line with ant i-UK rabbit IgG, and this line 
gave a reaction of ident ity with that produced with purified 
UK. As shown in Fig 8, the addition of purified UK to PAS 
exhibiting such a line merely enhanced the original precipitin 
arc, and no other precipitin lines were formed. As shown in Fig 
9, on immunoelectrophoresis PAS was found to have a mobility 
similar to that of pmified UK. 
DISCUSSION 
Since Astrup and Permin [28] reported the presence of an 
activator in a variety of animal t issues, many reports on tissue 
plasminogen activators have been accumulated. Recently, tis-
sue plasminogen activators have been confirmed not only in 
heart muscle [29], but also in the ovarium [30], endometrium 
[31], lung [32], and pancreas [33]. Histopathological study has 
demonstrated that the plasminogen activator activity in the 
skin was located in and around blood vessels in the middle and 
lower dermis. However, there are no reports except that of 
Friiki and Hopsu-Havu [34] which describe separation of plas-
minogen activator from psoriasis scales by purification and 
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FIG 7. Immunodiffu sion reactions of plasminogen activator in skin 
extract (PAS) and purified urokinase (UK) against anti-UK rabbit IgG. 
AS: anti-UK rabbit IgG (0.02 ml), I : pw·ified UK (5 Mg/ 0.02 ml), 2: 
purified UK (10 1-1gl , 3: PAS (5 1-1gl, 4: PAS (10 Mg). 
6 
5 1 
4 2 
3 
F I G 8. Immunodiffusion of a single plasminogen activator in skin 
extract (PAS) conta ining increasing amounts of added pur ified uroki -
nase (UK) againsl anti-UK rabbit lgG. AS: anti-UK rabbit IgG (0.02 
mll, I: PAS (5 !Lg/ 0.02 ml), 2: PAS (5 !Lgl + purified UK (2.5 !Lg) , 3: PAS 
(5 1-1gl + purified UK (5 1-1g), 4: PAS (5 1-1g) + purified UK (10 Mg) , 5: 
PAS (5 JLg) + purified UK (20 !Lg), .6: PAS (5 !-lg) +purified UK (40 /Lg). 
ascertainment of some of its biochemical and biophysical char-
acteristics. In the present study, the authors succeeded in 
extracting tissue glasminogen activator (PAS) fro m skin lesions. 
As shown in Table I, its plasminogen activator activity corre-
lated well with that of UK, and 0.1 ml of skin extract possessed 
an activity whk h corresponded to 10 IU of UK. On the other 
hand, although its arnidolytic activity coincided well with that 
of UK, only slight AGLMe esterolytic activity was detected. Its 
molecular weight" was determined to be about 110,000 by gel 
filtration on Sephadex G-200, which was obviously differe nt 
fro m that of UK (high molecular type; 53,000 and low molecular 
type; 33,000) [35]. From these resul ts, the a uthors sur mised 
that the difference of substrate specific ities between PAS and 
UK might be due to difference in molecular structm e, and not 
due to difference in active site. In an effor t to elucidate the 
identity of PAS in relation to UK, it was purified by successive 
column chromatography and PAGE, and its immunologic char-
Vo l. 78, No.1 1 
s 
3 
F I G 9. Immunoelectrophoresis of plasminogen activator in skin ex-
tract (PAS). AS: ant i-UK rabb it IgG , J: purified urokinase (UK) (1 0 
J.tg), 3: PAS (10 !Lgl , 4: PAS (20 1-1gl. 
acterization was also investigated. As shown in Fig 7, 8, and 9, 
it was confirmed that PAS is immunologically ident ical to UK. 
In 1968, K ucinski, Fletcher, and Sherry [36] immunized guinea 1 
pigs with human UK and used the resultan t antiserum to 
demonstrate t hat there was an antigenic dissimilarity among 
UK, plasma activator, and other plasminogen activators. They 
indicated that human plasma activator, milk activator, tissue 
activator from the adrenals and activators of bacterial origin 
were all immunologically distinct fro m human UK On the 
other hand, Astedt and Holmberg [37] reported that plasmin-
ogen activators with molecular weights of about 35,000 and 
52,000 were re leased in tissue culture of ovaria n carcinoma, and 
that they were immunologically identical to human UK based 
on the resul ts of neutralization and immunodiffusion experi-
ments with anti-UK rabbit serum. Despite the difference i11 
molecular weight, P AS as well as Astedt's plasminogen activa-
tor are considered to be very similar to, if not identical wi th 
UK AsP AS could not be extracted fro m the apparently healthy 
skin of patient or healthy persons, PAS must be an enzyme 1 
which is related to allergic vasculitis. Where then did PA 
originate? It has been repor ted by many workers [38-40] that 
the plasminogen activator is released from the vascular wall. 
Thus, it is possible that PAS may be produced in the vascular 
wall and released into t he blood and tissue space by disintegra· 
tion of the vascular wall following allergic vasculi tis. On the 
other hand , it has also been reported that the plasminogen , 
activator is produced in leukocytes [ 41,42] macrophages [ 43,44] 
and fibroblasts [ 45]. Therefore, there is another possibili ty that 
PAS may originate in polymorphonuclear leukocytes which is 
the chief infiltrating cell in the allergic vasculi t is lesion. This 
problem is under investigation on om laboratory. These results 
and facts indicate that the increase of blood fibrinolytic activity, 
such as significant shortening of EL T , in patients with allergic 
vasculi tis is responsible for the PAS demol)strated here. Thr 
role played by PAS in allergic vasculi tis, however, is still un· 
clear . 
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